Rachel A. Kudgus

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

Kara L. Davis, Elizabeth Fox, Melinda S. Merchant et al. · The Lancet Oncology · 2020 · 307 citations · Full text

Refractory Solid Tumours, Young Adults, Oncology +4

Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth

Sounik Saha, Xunhao Xiong, Prabir K. Chakraborty et al. · ACS Nano · 2016 · 155 citations · Full text

Nanoparticles, Nanotherapeutics, Engineering +24

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Steven G. DuBois, Araz Marachelian, Elizabeth Fox et al. · Journal of Clinical Oncology · 2016 · 132 citations

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Yaël P. Mossé, Elizabeth Fox et al. · Clinical Cancer Research · 2018 · 86 citations

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

Meredith K. Chuk, Brigitte C. Widemann, Charles G. Minard et al. · Pediatric Blood & Cancer · 2018 · 74 citations · Full text